welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).

expertly curated content related to this topic
-
New Combination Therapy Can Benefit Metastatic Colon CancerNew Combination Therapy Can Benefit Meta...
-
The Genetic Basis of Familial Adenomatous Polyposis and its Implications for Clinical Practice and Risk ManagementAmongst other F.A.P.-centric things, thi...
-
Is Laparoscopic Surgery an Option to Support Prophylactic Colectomy in Adolescent Patients with Familial Adenomatous...BACKGROUND : Prophylactic surgery is sti...
-
Stages and Evaluation of Surgical Innovation: A Clinical Example of the Ileo Neo Rectal Anastomosis After Ulcerative...AIM: So far, not many clinical examples...
-
J-Pouch Diet Blog Post from GUT-LESSWhile I cannot speak for everyone who li...
-
Study identifies enhanced impact of treatment for hereditary cancer patientsPeople with an inherited syndrome called...
-
Polyposis Syndromeshttp://www.slideshare.net/muzzain1/new-p...